Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced canc
- PDF / 727,298 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 164 Views
RESEARCH REPORT
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer Mingjia Li1 · Daniel Spakowicz2,3 · Songzhu Zhao3 · Sandip H. Patel2 · Andrew Johns4 · Madison Grogan2 · Abdul Miah2 · Marium Husain2 · Kai He2 · Erin M. Bertino2 · Peter G. Shields2 · Lai Wei3 · David P. Carbone2 · Gregory A. Otterson2 · Carolyn J. Presley2 · Dwight H. Owen2 Received: 29 May 2020 / Accepted: 16 July 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that may complicate treatment with immune checkpoint inhibitors (ICI) and can cause significant morbidity. We sought to identify predictors for the development of CIP, and whether the use of inhaled corticosteroids (ICS) at time of ICI may be protective. Methods Patients with advanced cancer treated with ICI from 2011 and 2018 were included in this study. CIP attribution to ICI was determined by treating physician at time of diagnosis. Predictors were assessed by univariate and multivariable Cox proportional hazard models. Results We identified 837 pts treated with ICI, of whom 30 (3.6%) developed grade 2 or higher CIP. 82 patients (9.8%) were receiving ICS at time of ICI and had increased risk of developing CIP with hazard ration (HR) of 4.22 (95% CI 1.93–9.21, p
Data Loading...
